Yahoo Finance Global Blood Screening Market to Reach $3.8 Billion by 2030
The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet.
New York, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Blood Screening Industry" - https://www.reportlinker.com/p05798062/?utm_source=GNW
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Global Blood Screening Market to Reach $3.8 Billion by 2030
In the changed post COVID-19 business landscape, the global market for Blood Screening estimated at US$2.4 Billion in the year 2022, is projected to reach a revised size of US$3.8 Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2022-2030. Reagents & Kits, one of the segments analyzed in the report, is projected to record a 6.6% CAGR and reach US$2.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Instruments segment is readjusted to a revised 3.7% CAGR for the next 8-year period.
The U.S. Market is Estimated at $660.9 Million, While China is Forecast to Grow at 9.6% CAGR
The Blood Screening market in the U.S. is estimated at US$660.9 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$847.7 Million by the year 2030 trailing a CAGR of 9.6% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2% and 6.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$516.3 Million by the year 2030.
Select Competitors (Total 12 Featured)
- Abbott Laboratories
- Beckman Coulter, Inc.
- Becton, Dickinson & Company
- bioMerieux SA
- Bio-Rad Laboratories, Inc.
- F. Hoffmann-La Roche AG
- Grifols International SA
- Ortho Clinical Diagnostics, Inc.
- Siemens Healthineers
- Thermo Fisher Scientific, Inc.
Read the full report: https://www.reportlinker.com/p05798062/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Blood Screening Market to Witness Moderate Growth
The Nucleic Acid Test (NAT) Segment to Register Highest Growth
Blood Screening - Global Key Competitors Percentage Market
Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Increase in Blood Donation Rates to Bode Well for Market Growth
Percentage of People Preferring to Donate Blood by Select
Countries: 2018
Various Initiatives to Donate Blood Propel Market Growth
Rising Incidence of Infectious Diseases
Total Number of Disease Cases Reported in the US due to
Infected Fleas, Ticks, and Mosquitoes: 2004-2016
Disease Response Towards Climate Change during the Recent Past
Opportunities and Challenges in Blood Screening
Innovations to Propel Market Growth
Various Measures for Ensuring Donated Blood Safety, a Key
Driver for Market Growth
Introduction of Novel Products to Support Market Growth
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Nucleic Acid Test (NAT) by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR
Table 2: World Historic Review for Nucleic Acid Test (NAT) by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 3: World 16-Year Perspective for Nucleic Acid Test (NAT)
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 4: World Recent Past, Current & Future Analysis for
Enzyme-Linked Immunosorbent Assay (ELISA) by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2022 through 2030 and
% CAGR
Table 5: World Historic Review for Enzyme-Linked Immunosorbent
Assay (ELISA) by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 6: World 16-Year Perspective for Enzyme-Linked
Immunosorbent Assay (ELISA) by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2014, 2023 & 2030
Table 7: World Recent Past, Current & Future Analysis for Rapid
Tests by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR
Table 8: World Historic Review for Rapid Tests by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 9: World 16-Year Perspective for Rapid Tests by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 10: World Recent Past, Current & Future Analysis for
Western Blot Assay by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 11: World Historic Review for Western Blot Assay by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 12: World 16-Year Perspective for Western Blot Assay by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 13: World Recent Past, Current & Future Analysis for
Next-Generation Sequencing (NGS) by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 14: World Historic Review for Next-Generation Sequencing
(NGS) by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 15: World 16-Year Perspective for Next-Generation
Sequencing (NGS) by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2014, 2023 & 2030
Table 16: World Recent Past, Current & Future Analysis for
Reagents & Kits by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 17: World Historic Review for Reagents & Kits by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 18: World 16-Year Perspective for Reagents & Kits by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 19: World Recent Past, Current & Future Analysis for
Instruments by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 20: World Historic Review for Instruments by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 21: World 16-Year Perspective for Instruments by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 22: World Recent Past, Current & Future Analysis for
Software & Services by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 23: World Historic Review for Software & Services by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 24: World 16-Year Perspective for Software & Services by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 25: World Recent Past, Current & Future Analysis for
Blood Banks by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 26: World Historic Review for Blood Banks by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 27: World 16-Year Perspective for Blood Banks by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 28: World Recent Past, Current & Future Analysis for
Hospitals by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 29: World Historic Review for Hospitals by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 30: World 16-Year Perspective for Hospitals by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030
Table 31: World Blood Screening Market Analysis of Annual Sales
in US$ Million for Years 2014 through 2030
Table 32: World Recent Past, Current & Future Analysis for
Blood Screening by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 33: World Historic Review for Blood Screening by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 34: World 16-Year Perspective for Blood Screening by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
UNITED STATES
Blood Screening Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in the United States for 2023 (E)
Table 35: USA Recent Past, Current & Future Analysis for Blood
Screening by Technology - Nucleic Acid Test (NAT),
Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western
Blot Assay and Next-Generation Sequencing (NGS) - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 36: USA Historic Review for Blood Screening by Technology -
Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay
(ELISA), Rapid Tests, Western Blot Assay and Next-Generation
Sequencing (NGS) Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2014 through 2021 and % CAGR
Table 37: USA 16-Year Perspective for Blood Screening by
Technology - Percentage Breakdown of Value Sales for Nucleic
Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA),
Rapid Tests, Western Blot Assay and Next-Generation Sequencing
(NGS) for the Years 2014, 2023 & 2030
Table 38: USA Recent Past, Current & Future Analysis for Blood
Screening by Product & Service - Reagents & Kits, Instruments
and Software & Services - Independent Analysis of Annual Sales
in US$ Million for the Years 2022 through 2030 and % CAGR
Table 39: USA Historic Review for Blood Screening by Product &
Service - Reagents & Kits, Instruments and Software & Services
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 40: USA 16-Year Perspective for Blood Screening by
Product & Service - Percentage Breakdown of Value Sales for
Reagents & Kits, Instruments and Software & Services for the
Years 2014, 2023 & 2030
Table 41: USA Recent Past, Current & Future Analysis for Blood
Screening by End-Use - Blood Banks and Hospitals - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 42: USA Historic Review for Blood Screening by End-Use -
Blood Banks and Hospitals Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR
Table 43: USA 16-Year Perspective for Blood Screening by
End-Use - Percentage Breakdown of Value Sales for Blood Banks
and Hospitals for the Years 2014, 2023 & 2030
CANADA
Table 44: Canada Recent Past, Current & Future Analysis for
Blood Screening by Technology - Nucleic Acid Test (NAT),
Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western
Blot Assay and Next-Generation Sequencing (NGS) - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 45: Canada Historic Review for Blood Screening by
Technology - Nucleic Acid Test (NAT), Enzyme-Linked
Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay
and Next-Generation Sequencing (NGS) Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 46: Canada 16-Year Perspective for Blood Screening by
Technology - Percentage Breakdown of Value Sales for Nucleic
Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA),
Rapid Tests, Western Blot Assay and Next-Generation Sequencing
(NGS) for the Years 2014, 2023 & 2030
Table 47: Canada Recent Past, Current & Future Analysis for
Blood Screening by Product & Service - Reagents & Kits,
Instruments and Software & Services - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 48: Canada Historic Review for Blood Screening by Product &
Service - Reagents & Kits, Instruments and Software &
Services Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 49: Canada 16-Year Perspective for Blood Screening by
Product & Service - Percentage Breakdown of Value Sales for
Reagents & Kits, Instruments and Software & Services for the
Years 2014, 2023 & 2030
Table 50: Canada Recent Past, Current & Future Analysis for
Blood Screening by End-Use - Blood Banks and Hospitals -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 51: Canada Historic Review for Blood Screening by End-Use -
Blood Banks and Hospitals Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR
Table 52: Canada 16-Year Perspective for Blood Screening by
End-Use - Percentage Breakdown of Value Sales for Blood Banks
and Hospitals for the Years 2014, 2023 & 2030
JAPAN
Blood Screening Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Japan for 2023 (E)
Table 53: Japan Recent Past, Current & Future Analysis for
Blood Screening by Technology - Nucleic Acid Test (NAT),
Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western
Blot Assay and Next-Generation Sequencing (NGS) - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 54: Japan Historic Review for Blood Screening by
Technology - Nucleic Acid Test (NAT), Enzyme-Linked
Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay
and Next-Generation Sequencing (NGS) Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 55: Japan 16-Year Perspective for Blood Screening by
Technology - Percentage Breakdown of Value Sales for Nucleic
Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA),
Rapid Tests, Western Blot Assay and Next-Generation Sequencing
(NGS) for the Years 2014, 2023 & 2030
Table 56: Japan Recent Past, Current & Future Analysis for
Blood Screening by Product & Service - Reagents & Kits,
Instruments and Software & Services - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 57: Japan Historic Review for Blood Screening by Product &
Service - Reagents & Kits, Instruments and Software &
Services Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 58: Japan 16-Year Perspective for Blood Screening by
Product & Service - Percentage Breakdown of Value Sales for
Reagents & Kits, Instruments and Software & Services for the
Years 2014, 2023 & 2030
Table 59: Japan Recent Past, Current & Future Analysis for
Blood Screening by End-Use - Blood Banks and Hospitals -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 60: Japan Historic Review for Blood Screening by End-Use -
Blood Banks and Hospitals Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR
Table 61: Japan 16-Year Perspective for Blood Screening by
End-Use - Percentage Breakdown of Value Sales for Blood Banks
and Hospitals for the Years 2014, 2023 & 2030
CHINA
Blood Screening Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in China for 2023 (E)
Table 62: China Recent Past, Current & Future Analysis for
Blood Screening by Technology - Nucleic Acid Test (NAT),
Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western
Blot Assay and Next-Generation Sequencing (NGS) - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 63: China Historic Review for Blood Screening by
Technology - Nucleic Acid Test (NAT), Enzyme-Linked
Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay
and Next-Generation Sequencing (NGS) Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 64: China 16-Year Perspective for Blood Screening by
Technology - Percentage Breakdown of Value Sales for Nucleic
Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA),
Rapid Tests, Western Blot Assay and Next-Generation Sequencing
(NGS) for the Years 2014, 2023 & 2030
Table 65: China Recent Past, Current & Future Analysis for
Blood Screening by Product & Service - Reagents & Kits,
Instruments and Software & Services - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 66: China Historic Review for Blood Screening by Product &
Service - Reagents & Kits, Instruments and Software &
Services Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 67: China 16-Year Perspective for Blood Screening by
Product & Service - Percentage Breakdown of Value Sales for
Reagents & Kits, Instruments and Software & Services for the
Years 2014, 2023 & 2030
Table 68: China Recent Past, Current & Future Analysis for
Blood Screening by End-Use - Blood Banks and Hospitals -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 69: China Historic Review for Blood Screening by End-Use -
Blood Banks and Hospitals Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR
Table 70: China 16-Year Perspective for Blood Screening by
End-Use - Percentage Breakdown of Value Sales for Blood Banks
and Hospitals for the Years 2014, 2023 & 2030
EUROPE
Blood Screening Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Europe for 2023 (E)
Table 71: Europe Recent Past, Current & Future Analysis for
Blood Screening by Technology - Nucleic Acid Test (NAT),
Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western
Blot Assay and Next-Generation Sequencing (NGS) - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 72: Europe Historic Review for Blood Screening by
Technology - Nucleic Acid Test (NAT), Enzyme-Linked
Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay
and Next-Generation Sequencing (NGS) Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 73: Europe 16-Year Perspective for Blood Screening by
Technology - Percentage Breakdown of Value Sales for Nucleic
Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA),
Rapid Tests, Western Blot Assay and Next-Generation Sequencing
(NGS) for the Years 2014, 2023 & 2030
Table 74: Europe Recent Past, Current & Future Analysis for
Blood Screening by Product & Service - Reagents & Kits,
Instruments and Software & Services - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 75: Europe Historic Review for Blood Screening by Product &
Service - Reagents & Kits, Instruments and Software &
Services Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 76: Europe 16-Year Perspective for Blood Screening by
Product & Service - Percentage Breakdown of Value Sales for
Reagents & Kits, Instruments and Software & Services for the
Years 2014, 2023 & 2030
Table 77: Europe Recent Past, Current & Future Analysis for
Blood Screening by End-Use - Blood Banks and Hospitals -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 78: Europe Historic Review for Blood Screening by End-Use -
Blood Banks and Hospitals Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR
Table 79: Europe 16-Year Perspective for Blood Screening by
End-Use - Percentage Breakdown of Value Sales for Blood Banks
and Hospitals for the Years 2014, 2023 & 2030
Table 80: Europe Recent Past, Current & Future Analysis for
Blood Screening by Geographic Region - France, Germany, Italy,
UK, Spain, Russia and Rest of Europe Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2022 through
2030 and % CAGR
Table 81: Europe Historic Review for Blood Screening by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 82: Europe 16-Year Perspective for Blood Screening by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2014, 2023 & 2030
FRANCE
Blood Screening Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in France for 2023 (E)
Table 83: France Recent Past, Current & Future Analysis for
Blood Screening by Technology - Nucleic Acid Test (NAT),
Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western
Blot Assay and Next-Generation Sequencing (NGS) - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 84: France Historic Review for Blood Screening by
Technology - Nucleic Acid Test (NAT), Enzyme-Linked
Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay
and Next-Generation Sequencing (NGS) Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 85: France 16-Year Perspective for Blood Screening by
Technology - Percentage Breakdown of Value Sales for Nucleic
Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA),
Rapid Tests, Western Blot Assay and Next-Generation Sequencing
(NGS) for the Years 2014, 2023 & 2030
Table 86: France Recent Past, Current & Future Analysis for
Blood Screening by Product & Service - Reagents & Kits,
Instruments and Software & Services - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 87: France Historic Review for Blood Screening by Product &
Service - Reagents & Kits, Instruments and Software &
Services Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 88: France 16-Year Perspective for Blood Screening by
Product & Service - Percentage Breakdown of Value Sales for
Reagents & Kits, Instruments and Software & Services for the
Years 2014, 2023 & 2030
Table 89: France Recent Past, Current & Future Analysis for
Blood Screening by End-Use - Blood Banks and Hospitals -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 90: France Historic Review for Blood Screening by End-Use -
Blood Banks and Hospitals Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR
Table 91: France 16-Year Perspective for Blood Screening by
End-Use - Percentage Breakdown of Value Sales for Blood Banks
and Hospitals for the Years 2014, 2023 & 2030
GERMANY
Blood Screening Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Germany for 2023 (E)
Table 92: Germany Recent Past, Current & Future Analysis for
Blood Screening by Technology - Nucleic Acid Test (NAT),
Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western
Blot Assay and Next-Generation Sequencing (NGS) - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 93: Germany Historic Review for Blood Screening by
Technology - Nucleic Acid Test (NAT), Enzyme-Linked
Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay
and Next-Generation Sequencing (NGS) Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 94: Germany 16-Year Perspective for Blood Screening by
Technology - Percentage Breakdown of Value Sales for Nucleic
Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA),
Rapid Tests, Western Blot Assay and Next-Generation Sequencing
(NGS) for the Years 2014, 2023 & 2030
Table 95: Germany Recent Past, Current & Future Analysis for
Blood Screening by Product & Service - Reagents & Kits,
Instruments and Software & Services - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 96: Germany Historic Review for Blood Screening by
Product & Service - Reagents & Kits, Instruments and Software &
Services Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 97: Germany 16-Year Perspective for Blood Screening by
Product & Service - Percentage Breakdown of Value Sales for
Reagents & Kits, Instruments and Software & Services for the
Years 2014, 2023 & 2030
Table 98: Germany Recent Past, Current & Future Analysis for
Blood Screening by End-Use - Blood Banks and Hospitals -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 99: Germany Historic Review for Blood Screening by
End-Use - Blood Banks and Hospitals Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 100: Germany 16-Year Perspective for Blood Screening by
End-Use - Percentage Breakdown of Value Sales for Blood Banks
and Hospitals for the Years 2014, 2023 & 2030
ITALY
Table 101: Italy Recent Past, Current & Future Analysis for
Blood Screening by Technology - Nucleic Acid Test (NAT),
Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western
Blot Assay and Next-Generation Sequencing (NGS) - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 102: Italy Historic Review for Blood Screening by
Technology - Nucleic Acid Test (NAT), Enzyme-Linked
Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay
and Next-Generation Sequencing (NGS) Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 103: Italy 16-Year Perspective for Blood Screening by
Technology - Percentage Breakdown of Value Sales for Nucleic
Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA),
Rapid Tests, Western Blot Assay and Next-Generation Sequencing
(NGS) for the Years 2014, 2023 & 2030
Table 104: Italy Recent Past, Current & Future Analysis for
Blood Screening by Product & Service - Reagents & Kits,
Instruments and Software & Services - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 105: Italy Historic Review for Blood Screening by Product &
Service - Reagents & Kits, Instruments and Software &
Services Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 106: Italy 16-Year Perspective for Blood Screening by
Product & Service - Percentage Breakdown of Value Sales for
Reagents & Kits, Instruments and Software & Services for the
Years 2014, 2023 & 2030
Table 107: Italy Recent Past, Current & Future Analysis for
Blood Screening by End-Use - Blood Banks and Hospitals -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 108: Italy Historic Review for Blood Screening by End-Use -
Blood Banks and Hospitals Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR
Table 109: Italy 16-Year Perspective for Blood Screening by
End-Use - Percentage Breakdown of Value Sales for Blood Banks
and Hospitals for the Years 2014, 2023 & 2030
UNITED KINGDOM
Blood Screening Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in the United Kingdom for 2023 (E)
Table 110: UK Recent Past, Current & Future Analysis for Blood
Screening by Technology - Nucleic Acid Test (NAT),
Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western
Blot Assay and Next-Generation Sequencing (NGS) - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 111: UK Historic Review for Blood Screening by Technology -
Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay
(ELISA), Rapid Tests, Western Blot Assay and Next-Generation
Sequencing (NGS) Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2014 through 2021 and % CAGR
Table 112: UK 16-Year Perspective for Blood Screening by
Technology - Percentage Breakdown of Value Sales for Nucleic
Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA),
Rapid Tests, Western Blot Assay and Next-Generation Sequencing
(NGS) for the Years 2014, 2023 & 2030
Table 113: UK Recent Past, Current & Future Analysis for Blood
Screening by Product & Service - Reagents & Kits, Instruments
and Software & Services - Independent Analysis of Annual Sales
in US$ Million for the Years 2022 through 2030 and % CAGR
Table 114: UK Historic Review for Blood Screening by Product &
Service - Reagents & Kits, Instruments and Software & Services
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 115: UK 16-Year Perspective for Blood Screening by
Product & Service - Percentage Breakdown of Value Sales for
Reagents & Kits, Instruments and Software & Services for the
Years 2014, 2023 & 2030
Table 116: UK Recent Past, Current & Future Analysis for Blood
Screening by End-Use - Blood Banks and Hospitals - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 117: UK Historic Review for Blood Screening by End-Use -
Blood Banks and Hospitals Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR
Table 118: UK 16-Year Perspective for Blood Screening by
End-Use - Percentage Breakdown of Value Sales for Blood Banks
and Hospitals for the Years 2014, 2023 & 2030
SPAIN
Table 119: Spain Recent Past, Current & Future Analysis for
Blood Screening by Technology - Nucleic Acid Test (NAT),
Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western
Blot Assay and Next-Generation Sequencing (NGS) - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 120: Spain Historic Review for Blood Screening by
Technology - Nucleic Acid Test (NAT), Enzyme-Linked
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05798062/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
